<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03551249</url>
  </required_header>
  <id_info>
    <org_study_id>BT008</org_study_id>
    <nct_id>NCT03551249</nct_id>
  </id_info>
  <brief_title>Assessment of Safety and Feasibility of ExAblate Blood-Brain Barrier (BBB) Disruption</brief_title>
  <official_title>Assessment of Safety and Feasibility of ExAblate Blood-Brain Barrier Disruption for the Treatment of High Grade Glioma in Patients Undergoing Standard Chemotherapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>InSightec</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>InSightec</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_unapproved_device>Yes</is_unapproved_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the safety of the ExAblate Model 4000 Type 2 used as&#xD;
      a tool to disrupt the BBB (blood brain barrier) in patients with high grade glioma undergoing&#xD;
      standard of care therapy.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a prospective, multi-center, single-arm study to establish the safety and feasibility&#xD;
      of BBB (blood brain barrier) disruption along the periphery of tumor resection cavity using&#xD;
      the ExAblate Neuro Model 4000 Type 2 (220 kHz) system. For this study, patients will be&#xD;
      eligible to enroll in the study prior to beginning the planned adjuvant TMZ chemotherapy&#xD;
      phase of treatment. Of note, only patients who are deemed eligible for adjuvant TMZ will be&#xD;
      eligible for enrollment.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 26, 2019</start_date>
  <completion_date type="Anticipated">December 2024</completion_date>
  <primary_completion_date type="Anticipated">March 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Device and procedure related adverse events</measure>
    <time_frame>Throughout the study, approximately 12 months.</time_frame>
    <description>The number and severity of device and BBB disruption procedure related adverse events will be evaluated and classified according to the CTCAE</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Feasibility of repeated BBB disruption will be evaluated through assessment of post-procedure contrast-enhanced magnetic resonance (MR) imaging</measure>
    <time_frame>At the time of each ExAblate MRgFUS procedure</time_frame>
    <description>The repeatability of BBB disruption will be evaluated at each of the 6 procedures and will be evaluated through assessment of post-procedure contrast-enhanced MR imaging.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Glioma</condition>
  <condition>Glioblastoma</condition>
  <arm_group>
    <arm_group_label>Focused Ultrasound (FUS)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The ExAblate Model 4000 Type 2 system is intended for use as a tool to induce localized and temporary blood-brain barrier disruption in patients with glioblastoma undergoing initial standard of care chemotherapy.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Focused ultrasound (FUS)</intervention_name>
    <description>FUS involves the application of acoustic energy at low frequencies from over 1000 individual transducers into distinct body targets.</description>
    <arm_group_label>Focused Ultrasound (FUS)</arm_group_label>
    <other_name>ExAblate, Type 2</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Patient is eligible for adjuvant temozolomide (TMZ) treatment based on the current&#xD;
             standard of care.&#xD;
&#xD;
          2. Men or women age between 18 and 80 years, inclusive.&#xD;
&#xD;
          3. Able and willing to give informed consent.&#xD;
&#xD;
          4. Grade IV glioma (GBM)&#xD;
&#xD;
          5. Combined radiation/TMZ treatment is completed based on the prescribed standard of care&#xD;
             regimen.&#xD;
&#xD;
          6. Karnofsky rating 70-100.&#xD;
&#xD;
          7. Able to communicate during the ExAblate BBBD (Blood Brain Barrier Disruption)&#xD;
             procedure.&#xD;
&#xD;
          8. Able to attend all study visits (i.e., life expectancy of at least 3 months).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patients presenting with the following imaging characteristics:&#xD;
&#xD;
             i. Evidence of acute intracranial hemorrhage.&#xD;
&#xD;
          2. The sonication pathway to the tumor involves:&#xD;
&#xD;
             i. Extensive scalp sores. ii. Clips or other metallic implanted objects in the skull&#xD;
             or the brain (brain implants)&#xD;
&#xD;
          3. The subject presents with symptoms and signs of increased intracranial pressure (e.g.,&#xD;
             headache, nausea, vomiting, lethargy, and papilledema).&#xD;
&#xD;
          4. Patients with cerebellar or brainstem tumors.&#xD;
&#xD;
          5. Patients with positive HIV status.&#xD;
&#xD;
          6. Significant depression not adequately controlled with medication and at potential risk&#xD;
             of suicide.&#xD;
&#xD;
          7. Patient receiving bevacizumab (Avastin) therapy.&#xD;
&#xD;
          8. Patients receiving treatment with corticosteroid doses greater than dexamethasone 24&#xD;
             mg daily (or equivalent).&#xD;
&#xD;
          9. Patients undergoing other concurrent therapies such as chemotherapy wafers,&#xD;
             immunotoxins delivered by convection-enhanced delivery, regionally administered gene&#xD;
             and viral therapies, immunotherapies, focal irradiation with brachytherapy,&#xD;
             stereotactic radiosurgery, laser interstitial thermotherapy, and tumor treatment&#xD;
             fields therapy.&#xD;
&#xD;
         10. Cardiac disease or unstable hemodynamics including:&#xD;
&#xD;
             i. Documented myocardial infarction within six months of enrollment. ii. Unstable&#xD;
             angina on medication. iii. Congestive heart failure. iv. Left ventricular ejection&#xD;
             fraction &lt;50%. v. History of a hemodynamically unstable cardiac arrhythmia. vi.&#xD;
             Cardiac pacemaker.&#xD;
&#xD;
         11. Severe hypertension (diastolic BP &gt; 100 on medication).&#xD;
&#xD;
         12. Anti-coagulant therapy, or medications known to increase risk of hemorrhage within&#xD;
             washout period prior to treatment.&#xD;
&#xD;
         13. History of a bleeding disorder, coagulopathy or with a history of spontaneous tumor&#xD;
             hemorrhage.&#xD;
&#xD;
         14. Cerebral or systemic vasculopathy, including intracranial thrombosis, vascular&#xD;
             malformation, cerebral aneurysm or vasculitis.&#xD;
&#xD;
         15. History of drug or alcohol use disorder.&#xD;
&#xD;
         16. Active seizure disorder or epilepsy (seizures despite medical treatment).&#xD;
&#xD;
         17. Known sensitivity to gadolinium-based contrast agents.&#xD;
&#xD;
         18. Known sensitivity to DEFINITYÂ® ultrasound contrast agent or perflutren.&#xD;
&#xD;
         19. Contraindications to MRI such as non-MRI-compatible implanted devices.&#xD;
&#xD;
         20. Large subjects not fitting comfortably into the MRI scanner.&#xD;
&#xD;
         21. Difficulty lying supine and still for up to 4 hours in the MRI unit or claustrophobia.&#xD;
&#xD;
         22. Positive pregnancy test (women of childbearing potential).&#xD;
&#xD;
         23. Severely impaired renal function or on dialysis.&#xD;
&#xD;
         24. Cardiac shunt.&#xD;
&#xD;
         25. Subjects with evidence of cranial or systemic infection.&#xD;
&#xD;
         26. Subjects with significant liver dysfunction, e.g., history of cirrhosis or active&#xD;
             hepatitis.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Graeme Woodworth, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Maryland, College Park</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Julia Zhu</last_name>
    <phone>972-421-0450</phone>
    <email>juliaz@insightec.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Kathy McDermott</last_name>
    <phone>972-421-0143</phone>
    <email>kathym@insightec.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of Maryland</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21201</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kaitlyn Henry</last_name>
      <phone>410-328-0939</phone>
      <email>KHenry@som.umaryland.edu</email>
    </contact>
    <contact_backup>
      <last_name>Charlie Klontz</last_name>
      <email>CMKlontz@som.umaryland.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Graeme Woodworth, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Brigham and Women's Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anna Ball</last_name>
      <phone>617-732-6992</phone>
      <email>aball@bwh.harvard.edu</email>
    </contact>
    <contact_backup>
      <last_name>Ana Montalvo Landivar</last_name>
      <phone>754-422-3432</phone>
      <email>amontalvolandivar@bwh.harvard.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Alexandra Golby, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Virginia</name>
      <address>
        <city>Charlottesville</city>
        <state>Virginia</state>
        <zip>22908</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Matthew Patterson</last_name>
      <phone>434-243-7336</phone>
      <email>MWP5F@hscmail.mcc.virginia.edu</email>
    </contact>
    <investigator>
      <last_name>Jason Sheehan, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>West Virginia University</name>
      <address>
        <city>Morgantown</city>
        <state>West Virginia</state>
        <zip>26506</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Clint Chiplinski</last_name>
      <phone>304-293-2991</phone>
      <email>clint.chiplinski@hsc.wvu.edu</email>
    </contact>
    <investigator>
      <last_name>Christopher P Cifarelli, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>April 17, 2018</study_first_submitted>
  <study_first_submitted_qc>June 6, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">June 11, 2018</study_first_posted>
  <last_update_submitted>June 24, 2021</last_update_submitted>
  <last_update_submitted_qc>June 24, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 28, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glioblastoma</mesh_term>
    <mesh_term>Glioma</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

